“New results on a possible COVID-19 vaccine from Oxford University and AstraZeneca suggest it is safe and about 70% effective, but questions remain about how well it may help protect those over 55 — a key concern for a vaccine that health officials hope to rely on around the world because of its low cost, availability and ease of use. 仍然, experts say the vaccine seems likely to be approved, despite some confusion in the results and lower levels of protection than what some other vaccine candidates have shown. “What we can see looks reasonable, but it’s a bit more complicated than what we’ve seen so far,” said Dr. Buddy Creech, a Vanderbilt University researcher helping to test two other vaccines. “If this had been the first report out, the field would have still been excited to have a vaccine.” The medical journal Lancet on Tuesday published partial results from tests of the vaccine in the United Kingdom, Brazil and South Africa — safety results on 23,745 participants and protection levels on 11,636. They’re hard to interpret because a mistake led some participants to get a half dose followed by a full one rather than two full doses as intended. Researchers claim the vaccine protected against disease in 62% of those given two full doses and in 90% of those initially given the half dose. 然而, independent experts have said the second group was too small — 2,741 people — to judge the possible value of that approach and that more testing is needed. The half-dose group also didn’t include anyone over 55, and among others in the study, only about 12% were in that age group. Older people also were enrolled later, so there hasn’t been enough time to see whether they develop infections at a lower rate than those not given the vaccine. It’s unclear if the results will be enough to lead regulators in the United Kingdom and elsewhere to approve its use right away. “We have no safety concerns about the vaccine,” with no hospitalizations or severe disease among those who received it, and results from all study locations consistently showing benefit, said one study leader, Oxford’s Andrew Pollard. “The only way we get the pandemic behind us is if we get doses of vaccine out there,“ 他说. AstraZeneca’s Mene Pangalos called the results “very compelling” and said they “clearly show we have an effective vaccine” that meets criteria for approval around the world. “I really believe this vaccine will have a big impact on the pandemic,“ 他说. In the study, 10 people were hospitalized for COVID-19, none of whom received the vaccine. Two were considered severe cases, and one person died. There were three serious side effects — a neurological problem in one person given the vaccine, anemia in one from the placebo group and severe fever in a participant whose receipt of vaccine or comparison shots is not yet known. All have recovered. The results come the same day that Britain started giving another vaccine, from Pfizer and Germany’s BioNTech. That vaccine and another developed by U.S. government scientists and made by Moderna Inc. seem about 95% effective in results announced so far. They work differently than AstraZeneca’s, which was developed by Oxford. “Personally I’d be happy with any of these in my arm,” Pollard said. Hopes are high for the AstraZeneca vaccine because it can be shipped and stored at normal refrigerator temperatures unlike the others that require freezing until a few hours before they’re given. That’s “very impractical” in developing countries, said Dr. Gillies O’Bryan-Tear of Britain’s Faculty of Pharmaceutical Medicine. In June, AstraZeneca said it could produce about 2 billion doses of the vaccine every year, with about half of that contracted to India’s Serum Institute for use in the developing world. AstraZeneca has also signed licensing deals for the vaccine to be produced in countries including Brazil, South Africa and China. COVAX, the global initiative led by the World Health Organization and vaccines alliance Gavi aimed at distributing COVID-19 vaccines to poorer countries, has signed an agreement to obtain about 400 million doses of the AstraZeneca vaccine. Associated Press writers Maria Cheng and Danica Kirka in London contributed to this report.
特朗普政府在新的 COVID-19 提议中降低失业救济金
144 观看次数0 评论1 喜欢
["白宫的最新刺激提议是一次性的 $600 大多数美国人的付款和失业者的一块煤. 财政部长史蒂夫·姆努钦 (Steve Mnuchin) 提出的新提案交换了 $3...
王牌: 数百万美国人感染 COVID-19 是“了不起的”’ 和“强大的疫苗”’
130 观看次数0 评论0 喜欢
["周二,唐纳德·特朗普总统将大量感染 COVID-19 的美国人称为“了不起的人”。,”错误地声称所有这些病例都是“强大的疫苗”。 “我认为疫苗 ...
2019冠状病毒病死亡, 佐治亚州选举和特朗普赦免: 赫芬顿邮报读者的观点
132 观看次数0 评论0 喜欢
["HuffPost 插图在最近的民意调查中, HuffPost 成员要求最高的功能之一是读者评论综述. 每周, HuffPost 编辑会阅读您对我们的头条新闻的评论,并突出显示那些....
我们. Regulators Post Positive Review Of Pfizer Vaccine Data
119 观看次数0 评论0 喜欢
["华盛顿 (美联社) — Documents released by U.S. regulators Tuesday confirmed that Pfizer and BioNTech’s COVID-19 vaccine was strongly protective against COVID-19 ― offering the world’s first detailed look at the eviden...
William Shakespeare Is Second Person To Receive Vaccine As UK Begins Shots
113 观看次数0 评论0 喜欢
["An historical occasion like the rollout of a coronavirus vaccine requires an historic name, right? Enter one William Shakespeare, an 81-year-old British man who on Tuesday became the second person in the world to re...
辉瑞拒绝白宫“疫苗峰会”的邀请’
85 观看次数0 评论0 喜欢
["辉瑞和Moderna, 两家开发出有前景的 COVID-19 疫苗的制药公司, 不会参加周二在白宫举行的吹捧私营部门参与的“疫苗峰会”。.
Trump Administration Declined Summer Offer To Buy More Of Pfizer’s Vaccine: 报告
73 观看次数0 评论0 喜欢
["The Trump administration declined an offer from Pfizer to buy more doses of its COVID-19 vaccine at the end of the summer, according to several reports. The New York Times first reported Monday that Pfizer offered t...
歌手 Jeremih 在 COVID-19 战斗后离开医院, 说他“永远感激”’
364 观看次数0 评论0 喜欢
["歌手 Jeremih 在逗留期间与 COVID-19 抗争后,已从芝加哥西北纪念医院出院, 他的家人说. 这位 33 岁的 R&B 艺术家, 本名杰瑞米·费尔顿, 谢谢...